drugset / Trial / NCT00332176
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to undertake an initial evaluation of the safety, tolerability, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin in patients with chronic HCV infection.
Timeline
- Start
- 2006-06
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celgosivir | Small molecule | 400 mg | — |
| Subject | Celgosivir | Small molecule | 600 mg | — |
| Comparator | Peginterferon alfa-2b | Protein / enzyme biologic | — | — |
| Comparator | Ribavirin | Small molecule | — | — |